Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2009-04-30 | Laura Brege 51 Director |
| 2010-04-23 | Laura Brege has served as a director of our company since May 2008. ... The Board of Directors has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. ... The following table shows for the fiscal year ended December 31, 2009 certain information with respect to the compensation of all persons who served as directors of the Company during the year, other than Dr. Hacksell, who is a Named Executive Officer and received no additional compensation for his services as a director: ... Laura Brege: Fees Earned or Paid in Cash includes $7,250 in Board of Directors and Audit Committee meetings fees and a $20,000 annual retainer paid in cash. Option Awards includes the fair value of 10,000 stock options granted on June 12, 2009 with an exercise price of $2.16. As of December 31, 2009, an aggregate of 35,000 stock options that had been granted to Ms. Brege were outstanding. |
| 2011-04-25 | Laura Brege 53 Director ... Director Compensation for Fiscal 2010 ... Laura Brege(4) Fees Earned or Paid in Cash includes $9,000 in Board of Directors and Audit Committee meetings fees. Option Awards includes the fair value of 10,000 stock options and 46,153 stock options (from the conversion of a $20,000 annual retainer) each granted on June 11, 2010 with an exercise price of $1.30. As of December 31, 2010, an aggregate of 91,153 stock options that had been granted to Ms. Brege were outstanding. |
| 2012-04-18 | Laura Brege ... Audit Committee ... Fees Earned or Paid in Cash includes $8,000 in Board of Directors and Audit Committee meetings fees. Option Awards includes the fair value of 10,000 stock options and 34,285 stock options (from the conversion of a $20,000 annual retainer) each granted on June 10, 2011 with an exercise price of $1.75. Total compensation was $67,732. |
| 2013-04-25 | Laura Brege has served as a director since May 2008. She is a member of the Audit Committee. Director Compensation for Fiscal 2012 shows Laura Brege earned $8,750 in cash and $57,429 in option awards, totaling $66,179. |
| 2014-04-23 | Laura Brege 56 Director |
| 2015-04-29 | Laura Brege has served as a director of our company since May 2008. ... The Board has an Audit Committee. Laura Brege Fees Earned or Paid in Cash includes Annual Retainer of $35,000 and Additional Retainer for Audit Member (non-Chair) of $9,000. Option Awards includes the fair value of 12,500 stock options granted on June 6, 2014 with an exercise price of $21.99. Total compensation $249,215. |
| 2016-04-29 | Laura Brege 58 Director The Board has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for 2015: Laura Brege X The Board of Directors has determined that Ms. Brege qualifies as an audit committee financial expert, as defined in applicable SEC rules. |
| 2017-04-27 | Laura Brege 59 Director |
| 2018-04-30 | Laura Brege(5) Fees Earned or Paid in Cash includes Annual Retainer of $50,000, Additional Retainer for Audit Chair of $20,000 and Additional Retainer for Nominating & Corporate Governance Member (non-Chair) of $5,000. Option Awards includes the fair value of 15,000 stock options granted June 13, 2017 with an exercise price of $27.25. As of December 31, 2017, an aggregate of 110,000 stock options that had been granted to Ms. Brege were outstanding. |
| 2019-04-30 | Laura Brege - Director, age 61. She serves on the Audit Committee (Chair) and Nominating and Corporate Governance Committee. 2018 compensation: $793,628. |
| Filing Date | Source Excerpt |
|---|---|
| 2015-04-21 | Laura Brege 57 Director ... Ms. Brege has been a member of our Board since February 2015. ... The Audit Committee for 2014 was composed of three directors: Dr. Gilbert (Chairperson), Dr. Oronsky and Ms. Phillips. Dr. Gilbert was the Chairperson of the Audit Committee until she resigned from the Board after the Audit Committee meeting effective March 5, 2015. Ms. Brege replaced Dr. Gilbert as the Chairperson of the Audit Committee. |
| 2016-04-22 | Laura Brege 58 Director ... Dr. Gilbert resigned from the Board after the Audit Committee meeting effective March 5, 2015, and Ms. Laura Brege became the chairperson of the Audit Committee thereafter ... The following table shows for the fiscal year ended December 31, 2015, certain information with respect to the compensation of all non-employee directors of the Company: Laura Brege $45,000 Fees Earned or Paid in Cash, $172,902 Option Awards, $217,902 Total. |
| 2017-04-21 | Laura Brege 59 Director ... The Audit Committee for 2016 was comprised of three directors: Ms. Brege (Chairperson), Dr. Oronsky and Ms. Phillips ... Our Compensation Committee is composed of three directors: Ms. Phillips (Chairperson) and Drs. Cano and Kisner ... The following table shows for the fiscal year ended December 31, 2016, certain information with respect to the compensation of all non-employee directors of the Company: Laura Brege $60,000 Fees Earned or Paid in Cash, $70,692 Option Awards, $130,692 Total. |
| 2017-07-10 | Laura Brege, Director |
| 2018-04-20 | Laura Brege 60 Director ... The Audit Committee for 2017 was comprised of three directors: Ms. Brege (Chairperson), Dr. Oronsky and Ms. Phillips ... The following table shows for the fiscal year ended December 31, 2017, certain information with respect to the compensation of all non-employee directors of the Company: Laura Brege $60,000 $29,203 $89,203 |
| 2019-04-22 | Our Board presently has eight members. There are three directors in the class whose term of office expires in 2019: Dennis A. Carson, M.D., Eddie Gray, and Laura Brege, each of whom is a nominee for director and currently a director of the Company. Dr. Carson, Mr. Gray and Ms. Brege were previously elected by the stockholders in 2016. If each nominee is elected at the Annual Meeting, each of these nominees will serve until the 2022 Annual Meeting and until his or her successor is elected and has qualified, or, if sooner, until the director's death, resignation or removal. We have a policy encouraging our directors' attendance at our annual meetings. There were six directors in attendance at our 2018 Annual Meeting. Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. The three nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the nominees named below. Although the election of directors at the Annual Meeting is uncontested and directors are elected by a plurality of votes cast, and we therefore anticipate that each of the named nominees for director will be elected at the Annual Meeting, under our Corporate Governance Guidelines, any nominee for director is required to submit an offer of resignation for consideration by the Nominating and Corporate Governance Committee if such nominee for director (in an uncontested election) receives a greater number of "Withhold" votes than "For" votes. In such case, the Nominating and Corporate Governance Committee will then consider all of the relevant facts and circumstances and recommend to the Board the action to be taken with respect to such offer of resignation. For more information on this policy see the section entitled "Corporate Governance." If any nominee becomes unavailable for election as a result of an unexpected occurrence, your shares will be voted for the election of a substitute nominee proposed by our Board. Each person nominated for election has agreed to serve if elected. Our Board has no reason to believe that any nominee will be unable to serve. Our Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Governance Committee. The following table provides membership and meeting information for fiscal year 2018 for each of the Board committees: Name Audit Compensation Nominating Laura Brege X * ... The following table shows for the fiscal year ended December 31, 2018, certain information with respect to the compensation of all non-employee directors of the Company: Name Fees Earned or Paid in Cash Option Awards Total Laura Brege $ 60,000 $ 156,767 $ 216,767 |
| Filing Date | Source Excerpt |
|---|---|
| 2013-04-25 | "Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago." |
| 2014-04-22 | "Ms. Brege held the roles of chief operating officer and executive vice president and chief business officer..." |
| 2015-04-21 | "Ms. Brege has served as a director since June 2011... Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago." |
| 2016-04-21 | "Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago." |
| 2017-04-21 | "Ms. Brege has been Managing Director of Cervantes Life Science Partners, LLC., a health care advisory and consulting company... Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago." |
| 2018-04-27 | "Ms. Brege has served as a director since June 2011... Managing Director of Cervantes Life Science Partners... President and Chief Executive Officer of Nodality..." |
| 2019-04-22 | "Ms. Brege has been Managing Director of Cervantes Life Science Partners, LLC., a health care advisory and consulting company... Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago." |
| 2020-04-24 | "Ms. Brege... served as Senior Advisor to BridgeBio Pharma... Managing Director of Cervantes Life Science Partners... Chief Executive Officer of Nodality... Ms. Brege earned her undergraduate degree... and has an M.B.A." |
| 2021-04-22 | “Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.” |
| 2022-04-22 | “Laura Brege Senior Advisor to BridgeBio Pharma, Inc.; and former Chief Executive Officer, Nodality, Inc.” |
| 2023-04-21 | “Laura Brege Senior Advisor to BridgeBio Pharma, Inc.; and former Chief Executive Officer, Nodality, Inc.” |
| 2024-04-22 | “We believe Ms. Brege’s qualifications to sit on our board include her financial expertise and her extensive experience in the pharmaceutical and biotechnology industries...” |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-04-25